 |
Journal articles
Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
Abstract : Recurrent miscarriage (RM), defined by three or more consecutive losses during the first trimester of pregnancy, affects 1%–2% of fertile couples. Standard investigations fail to reveal any apparent cause in ~50% of couples. However, on the basis of animal models and clinical studies, several hypotheses have been put forward concerning underlying mechanisms of RM: altered ovarian reserve, progesterone defect, thrombotic and/or endothelial dysfunction and immunological disturbances. Nonetheless, no study has yet reached conclusive beneficial clinical evidence for a potential treatment in unexplained RM. Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy. The pharmacological properties of HCQ (eg, antithrombotic, vascular protective, immunomodulatory, improved glucose tolerance, lipidlowering and anti-infectious) could be effective against some mechanisms of unexplained RM. Furthermore, eventhough clinical benefit of HCQ is suggested in prevention of thrombotic and late obstetric events in antiphospholipid (APL) syndrome, there are no data suggesting the benefit of HCQ in RM in the presence of APL antibodies.
Cited literature [61 references]
https://hal.univ-brest.fr/hal-02082511
Contributor : Ghislaine Calvez <>
Submitted on : Wednesday, December 11, 2019 - 3:42:15 PM
Last modification on : Friday, December 20, 2019 - 11:58:36 AM
Document(s) archivé(s) le : Thursday, March 12, 2020 - 9:05:43 PM
Contributor : Ghislaine Calvez <>
Submitted on : Wednesday, December 11, 2019 - 3:42:15 PM
Last modification on : Friday, December 20, 2019 - 11:58:36 AM
Document(s) archivé(s) le : Thursday, March 12, 2020 - 9:05:43 PM
File
e025649.full.pdf
Publisher files allowed on an open archive
Licence
Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
